Regain Biotechnology Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 20-12-2024
- Paid Up Capital ₹ 0.30 M
as on 20-12-2024
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 17.35%
(FY 2022)
- Ebitda
- Net Worth -0.02%
(FY 2022)
- Total Assets -0.04%
(FY 2022)
About Regain Biotechnology
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Elizabeth Frank, Reginold Bangera, Ramakrishna Kannan, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51909KA2004PTC034059
- Company No.
034059
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Mysore, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Regain Biotechnology?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Elizabeth Frank  | Managing Director | 01-Jun-2004 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Reginold Bangera | Director | 01-Jun-2004 | Current |
| Ramakrishna Kannan | Director | 03-Oct-2005 | Current |
| Cletus Dsouza | Director | 03-Oct-2005 | Current |
| Arthur Soans | Director | 30-Sep-2014 | Current |
Financial Performance of Regain Biotechnology.
Regain Biotechnology Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 17.35% increase in profit. The company's net worth dipped by a decrease of 0.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Regain Biotechnology?
In 2018, Regain Biotechnology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Laila Regain Bio Technologies Private LimitedActive 14 years 11 months
Elizabeth Frank is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Regain Biotechnology?
Unlock and access historical data on people associated with Regain Biotechnology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regain Biotechnology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regain Biotechnology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
